16PODM-207: A novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer. (23rd October 2018) - Moilanen, A; Lindqvist, J; Björkman, M; Riikonen, R; Nicorici, D; Mattila, E; Abbineni, C; Jaleel, M; Eriksson, J; Kallio, P